US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices
U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's popular diabetes and weight-loss medicines if the company lowered the list prices.
1d
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...
(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on ...
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback